The aim of the article was to report on the long-term follow-up of choroidal neovascularization (CNV) cases secondary to punctate inner choroidopathy (PIC) either treated with photodynamic therapy (PDT) or followed without treatment. A comprehensive review of existing literature on the various treatment modalities is incorporated. Methods: Nine eyes of 8 female patients with CNV due to PIC were followed retrospectively for an average of 105 months (range, 36-162 months). Mean age of the patient cohort on presentation was 28 years (range, 21-39). Four eyes were treated with PDT, whereas in 4 patients, including 1 with bilateral involvement, the disease followed its natural course without treatment. Snellen visual acuity and the extent of neovascularization and subretinal fibrosis were evaluated on presentation and at the end of the follow-up period. Results: Improvement of vision was observed in 6 eyes (66.7%), including all cases treated with PDT, and in 2 of 5 eyes left untreated. The size of the neovascular lesion, including both CNV and subretinal fibrosis, increased in all cases left untreated (55.6%) and remained stable in all cases treated with PDT (44.4%). Conclusion: Without treatment, the CNV due to PIC is slowly progressive. Our short cohort appears to have benefited from PDT in terms of maintaining visual acuity and stabilizing the extent of CNV and fibrosis.
Introduction
Punctate inner choroidopathy (PIC) is an inflammatory chorioretinal disease of unknown etiology, first described by Watzke et al in 1984 . 1 It presents mostly in healthy, young, moderately myopic women 2 with metamorphopsia and decreased visual acuity. On fundoscopy, small, creamy, yellow-white lesions, measuring 100-300 µm, located in the retinal pigment epithelium and inner choroid without concomitant intraocular inflammation are the hallmark of the early disease. 2 The optic nerve head can be mildly swollen. 3 Fluorescein angiography (FA) reveals areas with early hyperfluorescence and late leakage, 3 whereas, remarkably, on indocyanine green angiography, more hypofluorescent spots than observed clinically or on FA are evident, with normal large choroidal vessels running through the hypofluorescent areas. 3, 4 At least 25%-40% of patients develop choroidal neovascularization (CNV), usually within the first 6 months, although CNV may occur years after the initial lesions. For the remaining 60%-75%, the visual prognosis is rather favorable with the majority of eyes retaining vision of 20/30 or better. 2, 4, 5 This article was published in the following Dove Press journal: Clinical Ophthalmology 27 July 2010 Number of times this article has been viewed submit your manuscript | www.dovepress.com
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The variety of treatment options for the CNV in PIC reflects the puzzling absence of consistent results and includes submacular surgery, 6, 7 steroids, 4, 8, 9 photodynamic therapy (PDT), [10] [11] [12] [13] [14] [15] [16] and most recently anti-VEGF agents. 17, 18 In cases of extrafoveal or juxtafoveal lesion, CNV laser photocoagulation can also be attempted. 4 We report on the long-term outcome of a cohort of young adults with PIC complicated with CNV who either underwent PDT or left to follow the natural course of the disease.
Patients and methods
The charts of patients with a definite diagnosis of PIC from September 1993 were identified and reviewed. A total of 9 eyes of 8 patients with actively leaking CNV were included in the study and retrospectively followed for a total of 36-162 months (average, 105 months). In 1 patient, there was bilateral involvement, whereas in 7 patients, the CNV was unilateral. Four eyes were treated with PDT, and 5 eyes were left untreated. The latter was considered an established treatment modality for CNV, before the introduction of PDT. The patient who suffered bilateral involvement was also administered interferon-2b (IFN-2b; 3 MU subcutaneously 3 times per week) for viral hepatitis-B diagnosed during the initial workup, and 1 patient had been treated with thermal laser prior to PDT (Table 1) .
Treatment with PDT followed the standard protocol and consisted of an intravenous infusion of 6 mg/m 2 verteporfin (Visudyne  ; Novartis AG, Bülach, Switzerland) for 10 minutes. Fifteen minutes after the initiation of the infusion, the photosensitizer was activated using a laser light of 689 nm delivered at 50 J/cm 2 with an intensity of 600 mW/cm 2 for 83 seconds. The treatment spot was set to cover the greatest linear dimension of the CNV lesion, with an additional 500 µm covering the borders on each side. FA was performed prior to PDT to evaluate the extent of CNV and repeated during follow-up to evaluate the CNV activity. Retreatment was considered in cases of residual leakage or reactivation. Studied parameters included Snellen visual acuity and the extent of active neovascularization and subretinal fibrosis, as evaluated by reviewing the FA on presentation and at the end of follow-up period. Patient demographics, treatment, and final results are summarized in Table 1 . Figure 2A ) and several creamy, yellow-white lesions in the left eye with faint staining in the late phases of FA. None of the current treatment options was deemed effective, and the disease was left to follow its natural course. Three years later, an increase of the size of CNV was noted on FA, although visual acuity had improved to 20/30 OD. In subsequent follow-ups, visual acuity remained stable. Figure 2A ) and some scattered chorioretinal slightly pigmented small lesion in the left eye.
Results
report of selected cases
Nine eyes of 8 female patients were retrospectively followed for an average of 105 months (range, 36-162 months) after the diagnosis of PIC associated with active CNV. Mean age of the patient group was 28 years (range, 21-39). Four eyes were initially treated with PDT, in 3 of which the treatment was repeated once due to active leakage on subsequent FA. The remaining 5 eyes were followed without treatment mainly due to the lack of a widely accepted effective treatment at the time of presentation.
Visual acuity on presentation measured 20/40 or better in 2 eyes (22.2%), ranged from 20/40 to 20/200 in 4 eyes (44.4%), and was 20/200 or worse in 3 eyes (33.3%).
Improvement of vision was noted in 6 eyes at the end of the follow-up period (66.7%), including all cases treated with PDT, and in 2 of 5 eyes left untreated, and visual acuity deterioration was noted in 3 eyes (33.3%).
The size of the neovascular lesion, including both CNV and subretinal fibrosis, increased in 5 eyes (55.6%) and was stable in 4 eyes (44.4%) all treated with PDT. A trend toward better final visual acuity and stability of CNV activity was identified in the subgroup receiving PDT.
Discussion
The management of CNV due to PIC has not been conclusively determined, as most published cohorts (Table 2 ) report on small number of patients with short follow-up, including some with intermixed subfoveal and juxtafoveal CNV lesions. A variety of treatment options have been described, including PDT, [10] [11] [12] [13] [14] [15] [16] use of local and systemic steroid monotherapy, 2,4,9 submacular surgery, 6, 7 and recently anti-VEGF agents. 17, 18 Corticosteroids have also been advocated as a therapeutic adjunct to PDT, in particular due to their dual anti-inflammatory and antiangiogenetic properties. 19, 20 Oral steroids and laser photocoagulation were tried as early as 1984 by Watzke et al 1 in their initial presentation of 10 cases of a clinical entity that they termed "PIC". Brown et al 2 presented 5 patients who underwent oral and subtenon corticosteroid treatments, which reportedly slowed or stopped the subfoveal neovascularization, though without effect on final visual acuity which was less than 20/200 in all eyes. Submacular surgery was considered as a potential treatment of CNV due to PIC in 1995 by Adelberg et al, 7 who reported 1 case with more than 2 lines of Snellen acuity gain at the end of the follow-up period. Olsen et al 6 in 1996 reported further promising results in 5 patients (6 eyes) who underwent submacular surgery and noted visual improvement in all 6 eyes, although recurrences were common (4 out of 6 eyes). Sickenberg et al 11 in 2000 presented 1 case treated with PDT and followed for 35 weeks with no change in visual acuity (20/100), whereas Rogers et al 10 reported on 6 cases of PIC complicated with CNV and treated with PDT, and noted visual improvement in 4 eyes, decline in 1 and, stabilization in 1. Further reports on small cohorts of patients with PIC by Wachtlin et al, 12 Chatterjee and Gibson, 13 Postelmans et al, 14 Lim et al, 15 and Coco et al 16 substantiate a general trend toward favorable results with PDT. Fong et al 21 and Chan et al 22 reported encouraging results on combined PDT with oral or intravitreal steroid. Finally, Vossmerbaeumer et al 17 reported the successful outcome in a case of CNV secondary to PIC with intravitreal anti-VEGF treatment (bevacizumab), There is an apparent increase of choroidal neovascularization.
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PiC natural course and therapy and Leung et al 18 reported favorable results in a case with intravitreal ranibizumab after a short-term follow-up.
PDT is generally safe and effective for subfoveal CNV in age-related macular degeneration and high myopia. For other CNV etiologies, PDT is an option if outcome without treatment is likely to be poor, and preliminary success in ocular histoplasmosis syndrome, angioid streaks, idiopathic, and other conditions has been reported. 10, 11 Our results correlate with the ones reported by other authors [11] [12] [13] [14] [15] [16] further substantiating PDT as an effective treatment option in CNV due to PIC. It also adds to relevant literature a small but significant cohort of patients with long-term follow-up, which highlights the prolonged effectiveness of PDT in this patient group. The natural course of the disease is also demonstrated in our study with the presentation of a number of patients left untreated. Some of this group retained a functional visual acuity even after a long follow-up, implying that active neovascularization may recede leaving macula relatively unharmed.
Allowing for obvious limitations, such as the small number of cases and the retrospective review of patient records, our study contributes mainly with the long-term follow-up to the limited body of literature regarding CNV due to PIC.
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